A review of a protein called AXL in brain tumors
Original title: AXL at the nexus of therapeutic resistance, tumor vascularization, and immune evasion in cancer.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is a review of where the science is heading, not a new result in people.
The short version
Researchers think a protein called AXL helps tumors survive treatment.
What was studied. This is a review paper, not a new experiment. The authors gathered what is known about a protein called AXL in cancer, with a focus on glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary.
What they found. AXL is often switched on in tumors. It is rarely turned on by changes in genes. Instead, low oxygen, swelling, and cancer treatment itself seem to switch it on. The authors say AXL is not just sitting there. They think it helps a tumor adapt and keep going.
What this means, and what it doesn't
What it could mean: Drugs that block AXL are being studied, and some may be tried with other drugs. The hope is that blocking AXL could slow cancer cells, cut off their blood supply, and help the immune system fight back. For now that is a hope, not a proven result.
What it doesn't mean: This is not a new treatment, and it is not a cure. It is a summary of lab science and ideas about where research may go next. No one has shown here that blocking AXL helps people with brain tumors live longer. It is not something a doctor can offer you today.
Source: PubMed, September 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.